NSE · BAJAJHCARE · Healthcare
Bajaj HealthCare Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹562 Cr with net profit ₹39 Cr — a 7.03% net margin, versus -17.38% the period before.
Shareholding
As of 2026-06-30
- Promoter58.59%
- Public37.3%
- FII2.19%
- DII1.92%
41,310 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.98× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Drug Manufacturers - Specialty & Generic · ranked #1 of 15 by market cap
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Bajaj HealthCare Limited(this company) | — | 53.69 | 2.06 | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashBajaj HealthCare Limited, incorporated in 1993, is a pharmaceutical company that develops, manufactures, markets, and sells active pharmaceutical ingredients, intermediates, finished dosage forms, and nutraceuticals. The company serves the pharmaceutical, nutraceuticals, and food industries both in India and internationally. Its market capitalization is Rs 1243 Cr.
Positives
- +The profit margin is high at 280.81%.
- +Promoter holding of 58.59% indicates significant insider ownership.
- +The company has no promoter shares pledged.
Negatives
- −Revenue declined by 25.40% to Rs 482.10 Cr in March 2024 from Rs 647.39 Cr in March 2023.
- −The company reported a net loss of Rs 83.79 Cr in March 2024, resulting in a negative EPS of Rs -30.36.
- −The promoter holding has decreased from 67.26% in April 2019 to 58.59% in June 2026.
- −The company's P/E ratio is high at 53.69.
- −Quarterly results have not been consistently disclosed since March 2026.
Business Overview
Bajaj HealthCare Limited (BAJAJHCARE) is engaged in the development, manufacturing, marketing, and sale of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms, alongside nutraceuticals. The company's product portfolio covers a wide range of therapeutic categories including anti-diabetic, antibiotic, antiviral, antiplatelet, and antifungal agents, among others. It serves customers in India and global markets.
Financial Performance
The company reported revenue of Rs 611.03 Cr. The most recent annual revenue for March 2025 was Rs 562.01 Cr, following a decline to Rs 482.10 Cr in March 2024 from Rs 647.39 Cr in March 2023. Net profit for March 2025 stood at Rs 39.50 Cr, an improvement from a net loss of Rs 83.79 Cr in March 2024.
Profitability & Returns
Bajaj HealthCare Limited achieved a profit margin of 280.81%. The return on equity (ROE) was 8.81% and return on capital employed (ROCE) was 10.79%. Earnings per share (EPS) for the company stood at Rs 13.95. The company's PE ratio is 53.69.
Balance Sheet
The company has a book value of Rs 158.34. The debt-to-equity ratio is 0.75. Further details regarding assets and liabilities are not available in the provided data.
Ownership & Pledges
As of June 30, 2026, promoter holding in Bajaj HealthCare Limited was 58.59%. Public shareholding was 37.30%, while FIIs held 2.19% and DIIs held 1.92%. There were no promoter shares pledged as per the latest available data.
Data as of — price: 2026-07-29 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.